

Publication Date: 18.10.2019 17:00

EANS-Voting Rights: Marinomed Biotech AG / Publication of a participation notification according to art. 135 para. 2 Stock Exchange Act

Notification of voting rights transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.

Overview

1. Issuer: Marinomed Biotech AG
2. Reason for the notification: Acquisition or disposal of voting rights
3. Person subject to notification obligation
Name: Erste Asset Management GmbH
City: Wien
Country: Österreich
4. Name of shareholder(s): Erste Asset Management GmbH
5. Date on which the threshold was crossed or reached: 18.10.2019
6. Total positions

	% of voting rights attached to shares (7.A)	% of voting rights through financial/other instruments (7.B.1+_7.B.2)	Total of both in % (7.A + 7.B)	Total number of voting rights of issuer
Resulting situation on the date on which threshold was crossed / reached	7.71 %	0.00 %	7.71 %	1 469 772
Position of previous notification (if applicable)	0.00 %	0.00 %	0.00 %	

Details

7. Notified details of the resulting situation:

A: Voting rights attached to shares				
ISIN Code	Number of voting rights		% of voting rights	
	Direct (Sec 130 BörseG 2018)	Indirect (Sec 133 BörseG 2018)	Direct (Sec 130 BörseG 2018)	Indirect (Sec 133 BörseG 2018)
ATMARINOMED6	113 317		7.71 %	
SUBTOTAL A	113 317		7.71 %	

B 1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1 BörseG

2018				
Type of instrument	Expiration Date	Exercise Period	Number of voting rights that may be acquired if the instrument is exercised	% of voting rights
		SUBTOTAL B.1		

B 2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2 BörseG 2018					
Type of instrument	Expiration Date	Exercise Period	Physical / Cash Settlement	Number of voting rights	% of voting rights
			SUBTOTAL B.2		

8. Information in relation to the person subject to the notification obligation: Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

9. In case of proxy voting

Date of general meeting: -

Voting rights after general meeting: - is equivalent to - voting rights.

10. Additional comments:

The voting rights held by Erste Asset Management GmbH as stated in section 8 are not held directly but by the investment funds managed by the management company. They are therefore not holdings of the management company.

Note of the Issuer: This is a translation of the received shareholder notification in German language. The translation into English is not binding.

Further inquiry note:

Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
T +43 (0)1 250 77 4460
E-Mail: eva.prieschl@marinomed.com
<http://www.marinomed.com>

Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T +43 (0) 1 504 69 87 331
E-Mail: r.mayrl@metrum.at
<http://www.metrum.at>

end of announcement

euro adhoc

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: ATMARINOMED6, AT0000A1WD52
indexes:
stockmarkets: Wien
language: English



Aussendung übermittelt durch euro adhocal
The European Investor Relations Service